Paul B.  Manning net worth and biography

Paul Manning Biography and Net Worth

Paul B. Manning is an entrepreneur and businessperson who founded Able Laboratories, Inc., PBM Products LLC and PBM Capital Group LLC and who has been at the helm of 6 different companies. Presently, Mr. Manning holds the position of Chairman at Candel Therapeutics, Inc., Chairman of Xalud Therapeutics, Inc., Chairman for Verrica Pharmaceuticals, Inc. and Chairman and CEO at PBM Capital Group LLC.

He is also on the board of 9 other companies.

In his past career he occupied the position of Principal at Beta-Pro LLC, Chairman for Dova Pharmaceuticals, Inc., President & Chief Executive Officer for PBM Products LLC and Executive Vice President & General Manager at Perrigo Co.

Paul B. Manning received an undergraduate degree from the University of Massachusetts

What is Paul B. Manning's net worth?

The estimated net worth of Paul B. Manning is at least $42.66 million as of November 17th, 2023. Mr. Manning owns 16,566,667 shares of Taysha Gene Therapies stock worth more than $42,659,168 as of April 16th. This net worth approximation does not reflect any other assets that Mr. Manning may own. Learn More about Paul B. Manning's net worth.

How do I contact Paul B. Manning?

The corporate mailing address for Mr. Manning and other Taysha Gene Therapies executives is 2280 Inwood Road, DALLAS TX, 75235. Taysha Gene Therapies can also be reached via phone at 214-612-0000 and via email at [email protected]. Learn More on Paul B. Manning's contact information.

Has Paul B. Manning been buying or selling shares of Taysha Gene Therapies?

Paul B. Manning has not been actively trading shares of Taysha Gene Therapies during the last ninety days. Most recently, on Friday, November 17th, Paul B. Manning bought 100,000 shares of Taysha Gene Therapies stock. The stock was acquired at an average cost of $1.63 per share, with a total value of $163,000.00. Following the completion of the transaction, the insider now directly owns 16,566,667 shares of the company's stock, valued at $27,003,667.21. Learn More on Paul B. Manning's trading history.

Who are Taysha Gene Therapies' active insiders?

Taysha Gene Therapies' insider roster includes Kamran Alam (CFO), Phillip Donenberg (Director), Paul Manning (Director), Sean Nolan (Director), and R.A. Session, II (CEO). Learn More on Taysha Gene Therapies' active insiders.

Are insiders buying or selling shares of Taysha Gene Therapies?

In the last twelve months, Taysha Gene Therapies insiders bought shares 5 times. They purchased a total of 17,405,000 shares worth more than $15,736,400.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 419,689 shares worth more than $351,334.11. The most recent insider tranaction occured on November, 17th when Major Shareholder Paul B Manning bought 100,000 shares worth more than $163,000.00. Insiders at Taysha Gene Therapies own 2.3% of the company. Learn More about insider trades at Taysha Gene Therapies.

Information on this page was last updated on 11/17/2023.

Paul B. Manning Insider Trading History at Taysha Gene Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2023Buy100,000$1.63$163,000.0016,566,667View SEC Filing Icon  
8/16/2023Buy16,466,667$0.90$14,820,000.3016,466,667View SEC Filing Icon  
10/31/2022Buy1,500,000$2.00$3,000,000.001,642,202View SEC Filing Icon  
11/23/2021Buy20,000$12.54$250,800.00View SEC Filing Icon  
5/14/2021Buy12,000$20.98$251,760.00View SEC Filing Icon  
See Full Table

Paul B. Manning Buying and Selling Activity at Taysha Gene Therapies

This chart shows Paul B Manning's buying and selling at Taysha Gene Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Taysha Gene Therapies Company Overview

Taysha Gene Therapies logo
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $2.58
Low: $2.51
High: $2.70

50 Day Range

MA: $2.49
Low: $1.46
High: $3.25

2 Week Range

Now: $2.58
Low: $0.50
High: $3.89


1,475,393 shs

Average Volume

2,696,586 shs

Market Capitalization

$481.57 million

P/E Ratio


Dividend Yield